Results 1 to 10 of about 617,854 (310)

The epigenomics of sarcoma

open access: yesNature Reviews Cancer, 2020
Epigenetic regulation is critical to physiological control of development, cell fate, cell proliferation, genomic integrity, and fundamentally, transcriptional regulation. This epigenetic control occurs at multiple levels including through DNA methylation, histone modification, nucleosome remodeling, and modulation of the three-dimensional chromatin ...
B. Nacev   +8 more
semanticscholar   +5 more sources

Ewing sarcoma

open access: yesNature Reviews Disease Primers, 2018
Ewing sarcoma is the second most frequent bone tumour of childhood and adolescence that can also arise in soft tissue. Ewing sarcoma is a highly aggressive cancer, with a survival of 70-80% for patients with standard-risk and localized disease and ~30% for those with metastatic disease.
T. G. Grünewald   +8 more
semanticscholar   +5 more sources

Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers [PDF]

open access: yesJournal of Hematology & Oncology
Soft tissue and bone sarcomas are a heterogenous group of uncommon mesenchymal tumors with high unmet needs for novel therapeutic and diagnostic strategies. Despite many challenges that persist, innovative therapeutics are emerging.
Minggui Pan   +4 more
doaj   +2 more sources

Sarcoma [PDF]

open access: yesThe Oncologist, 2001
Abstract ASCO 2001 was a banner year for innovative systemic therapy for sarcomas. Imatinib mesylate (STI571, GleevecTM) shows clear activity not only in chronic myelogenous leukemia, for which the drug received Food and Drug Administration approval, but also in gastrointestinal stromal tumors as well, by virtue of imatinib mesylate ...
E O., Dickens, J M., McGeeE
openaire   +4 more sources

Synovial Sarcoma: A Clinical Review

open access: yesCurrent Oncology, 2021
Synovial sarcomas (SS) represent a unique subset of soft tissue sarcomas (STS) and account for 5–10% of all STS. Synovial sarcoma differs from other STS by the relatively young age at diagnosis and clinical presentation.
A. Gazendam   +5 more
semanticscholar   +1 more source

Sarcoma [PDF]

open access: yes, 2011
Sarcomas are a diverse group of malignancies originating in the connective tissue. The approach of a patient with a mass suspect for sarcoma starts with performing a biopsy to obtain tissue for evaluation by pathology. The main role of the current imaging modalities, in general, is to recognize patients with typically benign disease, in whom further ...
Ceyssens, Sarah, Stroobants, Sigrid
openaire   +4 more sources

Genome-wide CRISPR/Cas9 library screening identified ATM signaling network genes as critical drivers for resistance to ATR inhibition in soft-tissue sarcomas: synthetic lethality and therapeutic implications

open access: yesExperimental Hematology & Oncology, 2023
Soft-tissue sarcoma (STS) are a heterogeneous group of rare tumors with different biological behavior that are fatal in more than 40% of cases, due to their metastatic evolution and inadequate treatment options. ATR inhibition already showed an activity,
M Spalato-Ceruso   +8 more
doaj   +1 more source

Ewing Sarcoma

open access: yesSarcomas, 2020
Ewing sarcoma is a cancerous tumor that occurs in bones or soft tissues, such as cartilage or nerves. There are several types of Ewing sarcoma, including Ewing sarcoma of bone, extraosseous Ewing sarcoma, peripheral primitive neuroectodermal tumor (pPNET)
W. Alperstein, M. Trucco
semanticscholar   +1 more source

Histiocytic sarcoma [PDF]

open access: yesRevista Brasileira de Hematologia e Hemoterapia, 2010
A 59-year-old white woman, SC, after being treated for pneumonia, presented with an increase in the size of lymph nodes. The immunohistochemical examination diagnosed histiocytic sarcoma. Relapse occurred 12 months after starting chemotherapy. The patient evolved with febrile neutropenia, septic shock and death.
Machado, Eduardo Silva   +4 more
openaire   +5 more sources

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)

open access: yesFrontiers in Oncology, 2023
BackgroundIntratumoral injection of talimogene laherparepvec evokes a cytotoxic immune response. Therefore, the combination of talimogene laherparepvec with trabectedin and nivolumab may have synergistic effects in advanced sarcomas.Patients and ...
Sant P. Chawla   +13 more
doaj   +1 more source

Home - About - Disclaimer - Privacy